Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs YourHealthRx
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict72/ 100
Grade C · #123YourHealthRx
YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.
Visit YourHealthRxThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 72/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. YourHealthRx still earns its place — shoppers who want science-forward GLP-1 and peptide care nationwide, with flat-rate dosing and built-in clinical follow-up.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results85
92
Real-world results85
97Price honesty28
97
Price honesty28
96Prescriber access90
96
Prescriber access90
88Formulary choice88
88
Formulary choice88
95Cancellation fairness66
95
Cancellation fairness66
93Member support84
93
Member support84
Price, coverage & features
| Metric | CoreAge Rx | YourHealthRx |
|---|---|---|
| Verdict Score | 94/100 | 72/100 |
| Grade | A | C |
| Semaglutide | $149/mo | From $170/mo (compounded) |
| Tirzepatide | $349/mo | From $210/mo (compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | Yes |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
YourHealthRx
What we like
- Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
- Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
- Flat subscription price that doesn't change as your dose increases (no titration penalty)
- Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
- Transparent, education-first positioning with published medical disclaimer, privacy, and terms
The caveats
- Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
- Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
- Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
- No LegitScript certification displayed
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want science-forward GLP-1 and peptide care nationwide, with flat-rate dosing and built-in clinical follow-up.
Visit YourHealthRx Read the full YourHealthRx review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programmes closest to it, and the same shortlist for YourHealthRx does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.